Testosterone Deficiency in Men: Symptoms & TRT Guide

Testosterone Levels Have Fallen 1% Per Year Since the 1980s

Population-level data from the Massachusetts Male Aging Study and a 2007 Journal of Clinical Endocrinology and Metabolism analysis by Travison et al. document a secular decline in male testosterone levels of approximately 1% per year in US men since the 1980s — independent of age. A 60-year-old man in 2004 had testosterone levels roughly 17% lower than a 60-year-old man in 1987. The causes remain debated: rising obesity rates, environmental endocrine disruptors, sedentary behavior, and sleep disruption are all plausible contributors, likely acting in combination.

Against this backdrop, testosterone replacement therapy (TRT) prescriptions quintupled between 2000 and 2011, and the conversation about what constitutes deficiency has become genuinely contested — clinically, commercially, and scientifically.

Reference Ranges: What the Numbers Mean

Normal total testosterone in adult men is conventionally defined as 300–1,000 ng/dL (10.4–34.7 nmol/L), though laboratory reference ranges vary. The American Urological Association (AUA) and the Endocrine Society define hypogonadism as total testosterone consistently below 300 ng/dL on two morning measurements, combined with symptoms.

Total testosterone alone is an incomplete picture. Sex hormone-binding globulin (SHBG) binds testosterone tightly, reducing its bioavailability. Free testosterone — the unbound fraction, approximately 2–3% of total — and "bioavailable testosterone" (free + albumin-bound) are more functionally relevant. Men with normal total testosterone but elevated SHBG (common with aging, hyperthyroidism, and liver disease) can have functionally low free testosterone. The Endocrine Society recommends free or bioavailable testosterone measurement when total testosterone is borderline (200–400 ng/dL).

Symptoms Below 300 ng/dL

Symptoms of testosterone deficiency cover a broad spectrum and overlap substantially with normal aging, depression, and chronic illness — which complicates attribution. Sexual symptoms are the most specific: reduced libido, erectile dysfunction not explained by vascular disease, and reduced morning erections correlate better with low testosterone than do fatigue or mood changes.

• Sexual symptoms (most specific): decreased libido, erectile dysfunction, reduced morning erections, reduced ejaculatory volume
• Body composition changes: increased visceral fat, reduced lean muscle mass, reduced grip strength
• Mood and cognition: depressed mood, irritability, reduced motivation, cognitive slowing
• Physical signs: hot flashes, reduced body/facial hair, gynecomastia, testicular atrophy, reduced bone density
• Energy: fatigue and reduced stamina — the least specific symptom, present across dozens of conditions

The American Urology Association guidelines emphasize that diagnosis requires both biochemical confirmation AND symptoms. Treating a biochemically low testosterone in an asymptomatic man is not standard practice.

The Testosterone Trials: Seven Studies, One Landmark Program

The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled trials funded by the NIH, enrolling 788 men aged 65 and older with unequivocally low testosterone (<275 ng/dL) and age-related symptoms. Results published in the New England Journal of Medicine between 2016 and 2017 provided the highest-quality evidence to date on TRT in older men.

The cardiovascular finding — increased coronary artery noncalcified plaque volume — was concerning and has been a major driver of ongoing TRT cardiovascular safety research. The large TRAVERSE trial (2023), enrolling 5,246 men aged 45–80 with hypogonadism and high cardiovascular risk, found TRT was non-inferior to placebo for major adverse cardiovascular events over 33 months. However, it also found higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the TRT group.

TRT vs. Lifestyle: The Decision Framework

For men with testosterone in the 250–400 ng/dL range, lifestyle optimization merits a serious trial before pharmacological intervention. Resistance training increases testosterone by 15–25% acutely and produces modest but consistent long-term increases. Adequate sleep (7–9 hours) is essential — one week of sleep restriction to 5 hours/night reduces testosterone by 10–15% in young healthy men (Leproult & Van Cauter, JAMA 2011). Weight loss of 10% body mass can raise testosterone by 100–200 ng/dL in obese men.

When TRT is clinically indicated, delivery options include intramuscular injections (testosterone cypionate or enanthate, typically 100–200 mg every 1–2 weeks), topical gels (testosterone 1.62%, 2–4 pumps daily), transdermal patches, subcutaneous pellets, and intranasal gel. Each has distinct pharmacokinetic profiles, adherence characteristics, and transfer risks. Fertility impairment is a significant consideration: exogenous testosterone suppresses LH and FSH, halting spermatogenesis — a reversible but potentially slow reversal that must be discussed with men who wish to maintain fertility.

This article is for informational purposes only. Consult a qualified healthcare professional.